BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Press Releases

  AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026

  September 30, 2026

   · 

  8 min read
• Press Releases

  Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill

  September 30, 2026

   · 

  3 min read
• Press Releases

  ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

  September 30, 2026

   · 

  13 min read
• Press Releases

  Moderna Adds Chief Operating Officer Role as Company Expands into Oncology

  September 30, 2026

   · 

  5 min read
• Press Releases

  Compass Pathways Appoints Kelley Boucher as Chief People Officer

  September 30, 2026

   · 

  7 min read
• Press Releases

  Ocugen to Participate in Upcoming Scientific Conferences - September 30, 2026

  September 30, 2026

   · 

  3 min read
• Press Releases

  R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia

  September 30, 2026

   · 

  4 min read
• Press Releases

  EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application

  September 30, 2026

   · 

  3 min read
• Press Releases

  Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury

  September 30, 2026

   · 

  7 min read
• Press Releases

  Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

  September 30, 2026

   · 

  4 min read